Loading
Life sciences · Journal article
Colorectal Disease · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
AIM: Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real-world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who received anti-EGFR therapy during routine care. We further examined the association between these markers and the known predictive biomarkers of anti-EGFR efficacy, amphiregulin (AREG) and epiregulin (EREG). METHOD: The prognostic effects of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) were tested. The cohort was randomly partitioned into training and validation sets (1:1). Cutoff values were defined in the training set, with analyses repeated in the validation set. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate and disease control rate. RESULTS: 374 patients with RAS and BRAF wild-type mCRC who received treatment with cetuximab or panitumumab across eight UK centres were included. NLR (≤ 4 vs. > 4) and PLR (≤ 200 vs. > 200) were independently prognostic for both OS and PFS. SII (≤ 900 vs. > 900) gave the strongest prognostic signal (OS: adjusted HR 1.63 [1.26-2.11], p = 0.0002 and PFS: adjusted HR 1.62 [1.26-2.08], p = 0.0001). There were no associations between NLR or PLR with AREG or EREG, suggesting anti-EGFR benefit in AREG/EREG-high tumours is not related to systemic inflammation. CONCLUSION: Routinely assessed markers of systemic inflammation are independently prognostic in patients with mCRC receiving anti-EGFR therapy and may serve as useful adjuncts in informing discussions with patients about prognosis.